Etravirine
A non-nucleoside reverse transcriptase inhibitor.
General information
Etravirine on PubChem
![Structure image - Etravirine](/data/images/633.png)
CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N
Supporting references
Link | Tested on | Impact factor | Notes | Publication date |
---|---|---|---|---|
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model
Preprint In silico |
in silico | Feb/02/2020 | ||
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
3CLpro RdRpol Small molecule In silico |
in silico | 2.45 | Predicted to bind both SARS-CoV-2 3C-like protease and RNA-dependent RNA polymerase. It also possesses predicted good bioavailability. |
Oct/26/2020 |
AI-suggested references
Link | Publication date |
---|---|
Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.
|
Apr/06/2022 |
Tocilizumab in HIV patient with severe COVID-19: case report
|
Oct/16/2021 |